Blog | Page 2 of 2 | InSphero
July 18, 2018

Reaggregated human islets: the next gold standard in vitro model for diabetes research?

Correlating human pancreas donor characteristics with 3D InSight™ Islet Microtissue functionality confirms reaggregated islets are a robust, physiologically relevant model for diabetes research. With diabetes approaching epidemic proportions globally, there […]
June 29, 2018

Building a Better Model to Detect Mitochondrial Liabilities

InSphero and Agilent discuss the need for metabolically competent models with stable metabolic activity for mitochondrial toxicity testing in a new textbook chapter. Mitochondrial Dysfunction Caused by Drugs and Environmental […]
June 18, 2018

Why we need better preclinical models for NASH Drug Discovery

In honor of the inaugural International NASH Day, an initiative to raise awareness of nonalcoholic steatohepatitis (NASH), I thought it would be appropriate to reflect on the current status of […]
May 29, 2018

AstraZeneca and Genentech publish comprehensive evaluation of 3D spheroid hepatic cultures

Landmark study comparing 2D and 3D DILI models shows 3D InSight™ Human Liver Microtissues are a highly predictive liver toxicology model that outperforms 2D primary human hepatocytes in culture. In […]
May 28, 2018

InSphero Akura™ Flow: Transforming Drug Discovery and Development with Body-on-a-Chip Technology

InSphero Akura™ Flow body-on-a-chip technology may help make animal testing in pharma and cosmetic companies obsolete How can we better predict how new drugs act in the human body? This […]